Brayton Module Development Overview

The Advanced Gas Turbine (AGT) and the Subatmospheric Brayton Cycle (SABC) engines are under development. The AGT is developed for automotive applications while the SABC is developed for a gas fired heat pump application. Trade studies of the AGT, the SABC and other existing gas turbins are conducted in combination with various concentrators. The recommendation from these studies is to use the SABC for near term module development while following the AGT development for later advanced application. A preliminary design is completed at the module

Siting solar thermal power experiments

The Small Community Solar Thermal Power Experiment will test a point-focusing, distributed receiver system in a small community, electric utility application. Site planning is becoming increasingly important for solar experiments as well as all kinds of development due to increased competition for desirable sites and increased complexity of regulatory requirements. Siting issues can be categorized as: (1) resources and physical environmental at this site; (2) acquisition, permits and regulations; and (3) development requirements and costs. These issues are addressed with respect to the unique requirements of solar thermal power experiments

Siting Issues for Solar Thermal Power Plants with Small Community Applications

Technologies for solar thermal plants are being developed to provide energy alternatives for the future. Implementation of these plants requires consideration of siting issues as well as power system technology. While many conventional siting considerations are applicable, there is also a set of unique siting issues for solar thermal plants. Early experimental plants will have special siting considerations. The siting issues associated with small, dispersed solar thermal power plants in the 1 to 10 MWe power range for utility/small community applications are considered. Some specific requirements refer to the first 1 MWe engineering experiment for the Small Power Systems Applications (SPSA) Project. The siting issues themselves are discussed in three categories: (1) system resource requirements, (2) environmental effects on the system, and (3) potential impact of the plant on the environment. Within these categories, specific issues are discussed in a qualitative manner. Examples of limiting factors for some issues are taken from studies of other solar systems

Thermal power systems small power systems application project: Siting issues for solar thermal power plants with small community applications

The siting issues associated with small, dispersed solar thermal power plants for utility/small community applications of less than 10 MWe are reported. Some specific requirements are refered to the first engineering experiment for the Small Power Systems Applications (SPSA) Project. The background for the subsequent issue discussions is provided. The SPSA Project and the requirements for the first engineering experiment are described, and the objectives and scope for the report as a whole. A overview of solar thermal technologies and some technology options are discussed

Site participation in the small community experiment

The Small Community Solar Thermal Experiment, planned to test a small, developmental solar thermal power plant in a small community application, is assessed. The baseline plan is to install a field of parabolic dishes with distributed generation to provide 1 MWe of experimental power. Participation by the site proposer is an integral element of the experiment; the proposer will provide a ten-acre site, a connection to the electrical distributional system serving the small community, and various services. In addition to the primary participant, site study efforts may be pursued at as many as five alternative sites

Parabolic Dish Solar Thermal Power Annual Program Review Proceedings

The development and testing of concentrators, receivers, and power conversion units are reported. System design and development for engineering experiments are described. Economic analysis and market assessments for advanced development activities are discussed. Technology development issues and application/user needs are highlighted

Organometallic iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis

Platinum complexes related to cisplatin, cis-[PtCl2(NH3)2], are successful anticancer drugs; however, other transition metal complexes offer potential for combating cisplatin resistance, decreasing side effects, and widening the spectrum of activity. Organometallic half-sandwich iridium (IrIII) complexes [Ir(Cpx)(XY)Cl]+/0 (Cpx = biphenyltetramethylcyclopentadienyl and XY = phenanthroline (1), bipyridine (2), or phenylpyridine (3)) all hydrolyze rapidly, forming monofunctional G adducts on DNA with additional intercalation of the phenyl substituents on the Cpx ring. In comparison, highly potent complex 4 (Cpx = phenyltetramethylcyclopentadienyl and XY = N,N-dimethylphenylazopyridine) does not hydrolyze. All show higher potency toward A2780 human ovarian cancer cells compared to cisplatin, with 1, 3, and 4 also demonstrating higher potency in the National Cancer Institute (NCI) NCI-60 cell-line screen. Use of the NCI COMPARE algorithm (which predicts mechanisms of action (MoAs) for emerging anticancer compounds by correlating NCI-60 patterns of sensitivity) shows that the MoA of these IrIII complexes has no correlation to cisplatin (or oxaliplatin), with 3 and 4 emerging as particularly novel compounds. Those findings by COMPARE were experimentally probed by transmission electron microscopy (TEM) of A2780 cells exposed to 1, showing mitochondrial swelling and activation of apoptosis after 24 h. Significant changes in mitochondrial membrane polarization were detected by flow cytometry, and the potency of the complexes was enhanced ca. 5× by co-administration with a low concentration (5 μM) of the γ-glutamyl cysteine synthetase inhibitor L-buthionine sulfoximine (L-BSO). These studies reveal potential polypharmacology of organometallic IrIII complexes, with MoA and cell selectivity governed by structural changes in the chelating ligands

Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative

Background: The European NCI compounds programme, a joint initiative of the EORTC Research Branch, Cancer Research Campaign and the US National Cancer Institute, was initiated in 1993. The objective was to help the NCI in reducing the backlog of in vivo testing of potential anticancer compounds, synthesised in Europe that emerged from the NCI in vitro 60-cell screen. Methods: Over a period of more than twenty years the EORTC—Cancer Research Campaign panel reviewed ~2000 compounds of which 95 were selected for further evaluation. Selected compounds were stepwise developed with clear go/no go decision points using a pharmacologically directed programme. Results: This approach eliminated quickly compounds with unsuitable pharmacological properties. A few compounds went into Phase I clinical evaluation. The lessons learned and many of the principles outlined in the paper can easily be applied to current and future drug discovery and development programmes. Conclusions: Changes in the review panel, restrictions regarding numbers and types of compounds tested in the NCI in vitro screen and the appearance of targeted agents led to the discontinuation of the European NCI programme in 2017 and its transformation into an academic platform of excellence for anticancer drug discovery and development within the EORTC-PAMM group. This group remains open for advice and collaboration with interested parties in the field of cancer pharmacology

Low-fidelity DNA synthesis by the L979F mutator derivative of Saccharomyces cerevisiae DNA polymerase ζ

To probe Pol ζ functions in vivo via its error signature, here we report the properties of Saccharomyces cerevisiae Pol ζ in which phenyalanine was substituted for the conserved Leu-979 in the catalytic (Rev3) subunit. We show that purified L979F Pol ζ is 30% as active as wild-type Pol ζ when replicating undamaged DNA. L979F Pol ζ shares with wild-type Pol ζ the ability to perform moderately processive DNA synthesis. When copying undamaged DNA, L979F Pol ζ is error-prone compared to wild-type Pol ζ, providing a biochemical rationale for the observed mutator phenotype of rev3-L979F yeast strains. Errors generated by L979F Pol ζ in vitro include single-base insertions, deletions and substitutions, with the highest error rates involving stable misincorporation of dAMP and dGMP. L979F Pol ζ also generates multiple errors in close proximity to each other. The frequency of these events far exceeds that expected for independent single changes, indicating that the first error increases the probability of additional errors within 10 nucleotides. Thus L979F Pol ζ, and perhaps wild-type Pol ζ, which also generates clustered mutations at a lower but significant rate, performs short patches of processive, error-prone DNA synthesis. This may explain the origin of some multiple clustered mutations observed in vivo